Current Opinion in Infectious Diseases
October 2019 – Volume 32 – Issue 5
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
The first licensed dengue vaccine: can it be used in travelers?
Wilder-Smith, Annelies
Current Opinion in Infectious Diseases. 32(5):394-400, October 20
Current Opinion in Infectious Diseases
October 2019 – Volume 32 – Issue 5
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
WHO’s new rabies recommendations: implications for high incidence countries
Pattanaik, Amrita; Mani, Reeta S.
Current Opinion in Infectious Diseases. 32(5):401-406, October 2019.
Recent findings The key changes in the updated WHO 2018 guidelines for rabies prophylaxis include abbreviated vaccination regimens for pre and postexposure prophylaxis. These cost and dose-sparing regimens allow equitable sharing of vaccines, necessitate fewer clinic visits and thus can enhance patient compliance. The recommendations on rabies immunoglobulin administration permit prioritization and optimal use of this life-saving biologic, especially in areas with scarcity. However, there is a need for additional evidence to support the abridgment of some regimens and need for data on the safety and immunogenicity of these regimens in special groups such as infants and the immunocompromised.
Current Opinion in Infectious Diseases
October 2019 – Volume 32 – Issue 5
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
GASTROINTESTINAL INFECTIONS
Edited by Gagandeep Kang and Eric R. Houpt
Current and new rotavirus vaccines
Burke, Rachel M.; Tate, Jacqueline E.; Kirkwood, Carl D.; More
Current Opinion in Infectious Diseases. 32(5):435-444, October 2019.
PAEDIATRIC AND NEONATAL INFECTIONS
Edited by Saul N. Faust
Current Opinion in Infectious Diseases
October 2019 – Volume 32 – Issue 5
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
Meningitis vaccines in children: what have we achieved and where next?
McAlpine, Alastair; Sadarangani, Manish
Current Opinion in Infectious Diseases. 32(5):510-516, October 2019.
Emerging Infectious Diseases
Volume 25, Number 9—September 2019
http://wwwnc.cdc.gov/eid/
Research Letter
Worldwide Reduction in MERS Cases and Deaths since 2016
Christl A. Donnelly, Mamun R. Malik, Amgad Elkholy, Simon Cauchemez, and Maria D. Van
Abstract
Since 2012, Middle East respiratory syndrome (MERS) coronavirus has infected 2,442 persons worldwide. Case-based data analysis suggests that since 2016, as many as 1,465 cases and 293–520 deaths might have been averted. Efforts to reduce the global MERS threat are working, but countries must maintain vigilance to prevent further infections.
Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 7 Sep2019]
Review
| 3 September 2019
Preparedness and management of global public health threats at points of entry in Ireland and the EU in the context of a potential Brexit
We review the current situation (March 2019) with respect to detection and management of serious human health threats across Irish borders- and what may change for Ireland if/when the United Kingdom (UK) withdraws from the EU (Brexit).
Authors: Máirín Boland and Mary O’Riordan
Health Policy and Planning
Volume 34, Issue 6, July 2019
https://academic.oup.com/heapol/issue/34/6
Original Articles
The cost of not breastfeeding: global results from a new tool
Dylan D Walters, Linh T H Phan, Roger Mathisen
Health Policy and Planning, Volume 34, Issue 6, July 2019, Pages 407–417, https://doi.org/10.1093/heapol/czz050
Abstract
… Aggregating these costs, the total global economic losses are estimated to be US$341.3 billion, or 0.70% of global gross national income. While the aim of the tool is to capture the majority of the costs, the estimates are likely to be conservative since economic costs of increased household caregiving time (mainly borne by women), and treatment costs related to other diseases attributable to not breastfeeding according to recommendations are not included in the analysis. This study illustrates the substantial costs of not breastfeeding, and potential economic benefits that could be generated by government and development partners’ investments in scaling up effective breastfeeding promotion and support strategies.
Health Policy and Planning
Volume 34, Issue 6, July 2019
https://academic.oup.com/heapol/issue/34/6
Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study
Fatima Tauqeer, Kirsten Myhr, Unni Gopinathan
Health Policy and Planning, Volume 34, Issue 6, July 2019, Pages 440–449, https://doi.org/10.1093/heapol/czz054
Health Policy and Planning
Volume 34, Issue 6, July 2019
https://academic.oup.com/heapol/issue/34/6
Reviews
Mapping health workforce development strategies across key global health agencies: an assessment of objectives and key interventions
Brooke A Farrenkopf, Chung-Won Lee
Health Policy and Planning, Volume 34, Issue 6, July 2019, Pages 461–468, https://doi.org/10.1093/heapol/czz015
International Journal of Infectious Diseases
August 2019 Volume 85, p1-214
https://www.ijidonline.com/issue/S1201-9712(19)X0011-9
Editorial
Ebola in the DRC one year later – Boiling the frog?
Susan McLellan, Mark G. Kortepeter, Nahid Bhadelia, Erica S. Shenoy, Lauren M. Sauer, Maria G. Frank, Theodore J. Cieslak
p212–213
Published online: July 19, 2019
… In summary, security concerns in DRC provide a significant barrier to outbreak assistance; however, maintaining the current level of international engagement is likely to allow the outbreak to continue to spread within DRC, and eventually to neighboring and in turn distant countries. This will not be the last outbreak of Ebola in the DRC or elsewhere. It is to our benefit to seek ways to demonstrate this is not another case of “helicopter” intervention, but a long-term commitment for humanitarian aid and to bolster the health care system overall in DRC and develop sustainable response strategies that can be deployed to other communicable disease outbreaks in the future.
A deliberate, thoughtful scale-up of involvement in support of and in collaboration with partners on the ground, including the WHO and DRC government would ensure a seamless effort that is responsive to the communities’ and partners’ needs and help tip the scales. Such a demonstration would go a long way in winning the hearts and minds and cooperation of the local population who are there for the long term.
International Journal of Infectious Diseases
August 2019 Volume 85, p1-214
https://www.ijidonline.com/issue/S1201-9712(19)X0011-9
Reviews
Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease
Philip S. Watson, Patricia L. Novy, Leonard R. Friedland
p22–27
Published online: May 15, 2019
JAMA
September 3, 2019, Vol 322, No. 9, Pages 795-900
http://jama.jamanetwork.com/issue.aspx
Original Investigation
N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care PersonnelA Randomized Clinical Trial
Lewis J. Radonovich Jr, MD; Michael S. Simberkoff, MD; Mary T. Bessesen, MD; et al.
JAMA. 2019;322(9):824-833. doi:10.1001/jama.2019.11645
This cluster randomized clinical trial compares the effect of N95 respirators vs medical masks worn by health care personnel for prevention of workplace-acquired influenza and other viral respiratory infections in geographically diverse, high-exposure outpatient settings.
JAMA
September 3, 2019, Vol 322, No. 9, Pages 795-900
http://jama.jamanetwork.com/issue.aspx
Editorial
Respiratory Protection of Health Care Personnel to Prevent Respiratory Viral Transmission
Thomas R. Talbot, MD, MPH; Hilary M. Babcock, MD, MPH
JAMA
September 3, 2019, Vol 322, No. 9, Pages 795-900
http://jama.jamanetwork.com/issue.aspx
Viewpoint
Harms From Uninformative Clinical Trials
Deborah A. Zarin, MD; Steven N. Goodman, MD, MHS, PhD; Jonathan Kimmelman, PhD
JAMA. 2019;322(9):813-814. doi:10.1001/jama.2019.9892
This Viewpoint discusses key features of and incentives for randomized clinical trials (RCTs) that make many of them uninformative; reviews the challenges uninformative trials pose to ethics, science, and medical practice; and recommends what academic medical centers and funders can do to incentivize the conduct of RCTs that provide valid information that informs clinical practice.
JAMA Pediatrics
September 2019, Vol 173, No. 9, Pages 807-900
http://archpedi.jamanetwork.com/issue.aspx
Original Investigation
Implications of Changing Public Charge Immigration Rules for Children Who Need Medical Care
Leah Zallman, MD, MPH; Karen E. Finnegan, PhD; David U. Himmelstein, MD; et al.
online only
JAMA Pediatr. 2019;173(9):e191744. doi:10.1001/jamapediatrics.2019.1744
This cross-sectional study simulates the number, medical conditions, and care needs of children who are at risk of losing their current benefits, including Medicaid and Children’s Health Insurance Program and Supplemental Nutrition Assistance Program, after a proposed US federal rule change.
Journal of Community Health
Volume 44, Issue 5, October 2019
https://link.springer.com/journal/10900/44/5
Original Paper
The Male Voice: A Qualitative Assessment of Young Men’s Communication Preferences About HPV and 9vHPV
Jennifer A. Sledge, Claire E. Jensen, Nancy J. Cibulka…
Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 7 Sep2019]
Research
| 4 September 2019
Assessing national governance of medicine promotion: an exploratory study in Ghana to trial a structured set of indicators
Authors: Marcia McLean, Jillian Clare Kohler and Danny Edwards
Background
Two billion people worldwide, predominantly in low- and middle-income countries, cannot consistently access required essential medications, thus affecting their ability to attain optimal health outcomes. Access to appropriate medicines may be compromised due to issues involving cost, availability, quality, and prescribing practices, and system-wide factors such as a lack of transparency and accountability. Pharmaceutical promotional practices impact many of these issues, thus influencing the use of appropriate medicines,. Good governance is ultimately the responsibility of national governments through strong health systems with transparent and accountable practices that facilitate appropriate medicine use. We designed a structured set of indicators, based on existing tools, to assess the strength of the national governance of pharmaceutical promotion. In this exploratory study, we trialed the indicators in Ghana.
Journal of Public Health Management & Practice
September/October 2019 – Volume 25 – Issue 5
https://journals.lww.com/jphmp/pages/currenttoc.aspx
State of Public Health
Blinding Me With Science: Complementary “Head” and “Heart” Messages Are Needed to Counter Rising Vaccine Hesitancy
Fraser, Michael R.
Journal of Public Health Management and Practice. 25(5):511-514, September/October 2019.
Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6
Editor’s Choice
What is the prospect of a safe and effective dengue vaccine for travellers?
Anna P Durbin, MD, Duane J Gubler, ScD
Journal of Travel Medicine, Volume 26, Issue 6, 2019, tay153, https://doi.org/10.1093/jtm/tay153
Dengue affects hundreds of millions of persons each year and is a risk for travellers to dengue-endemic regions. The first licensed dengue vaccine is approved for use only in persons who are known to have had previous dengue infection, limiting its potential for use in travellers. Two other dengue vaccines are currently in Phase 3 clinical trials, with preliminary efficacy results expected soon. These vaccines differ from the currently licensed vaccine and, should they demonstrate efficacy, may offer the possibility of a dengue vaccine for travellers.
Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6
Addressing vaccine hesitancy in travellers: The CARD™ System
Anna Taddio, PhD, Noni MacDonald, MD
Journal of Travel Medicine, Volume 26, Issue 6, 2019, taz056, https://doi.org/10.1093/jtm/taz056
Current vaccination programs do not fully incorporate client-centred care in the delivery of vaccinations; hence, do not address vaccination hesitancy. This article provides a summary of a novel client-centred approach to vaccinations to improve the vaccination experience and promote vaccination.
Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6
Perspectives
Yellow fever vaccination for immunocompromised travellers: unjustified vaccination hesitancy?
Wesley de Jong, MD, Rob A de Man, MD PhD, Virgil A S H Dalm, MD PhD, Chantal B E M Reusken, PhD, Marco Goeijenbier, MD PhD …
Journal of Travel Medicine, Volume 26, Issue 6, 2019, taz015, https://doi.org/10.1093/jtm/taz015
Improved quality of life in immunocompromised patients opens travel opportunities, but administering the yellow fever (YF) vaccine is often contraindicated. We advocate re-evaluating this position for immunocompromised patients who travel frequently or who are migrating to regions in which YF is endemic.
Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6
Fractional-dose yellow fever vaccination: an expert review
Anna H E Roukens, MD, PhD, Leo G Visser, MD, PhD
Journal of Travel Medicine, Volume 26, Issue 6, 2019, taz024, https://doi.org/10.1093/jtm/taz024
Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6
Seroprotection rates of vaccine-preventable diseases among newly arrived Eritrean asylum seekers in Switzerland: a cross-sectional study
Cornelia Staehelin, MD, MIH, Afona Chernet, PhD, Véronique Sydow, MD, Rein J Piso, MD, Franziska Suter-Riniker, PhD …
Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6
Rapid Communication
Measles and the 2019 Hajj: the risk of magnifying the global measles surge
Ziad A Memish, MD, FRCPC, FRCPE, FRCPL, FACP, FFPH, Anas A Khan, MD, Shahul Ebrahim, MD, MSc, PhD
Journal of Travel Medicine, Volume 26, Issue 6, 2019, taz041, https://doi.org/10.1093/jtm/taz041
The projected linear increases in Muslim pilgrims for Hajj and Umra to Saudi Arabia from current 7 million to 30 million by 2030 will increase the density of pilgrims and the potential for infectious disease transmission. Because pilgrims originate from over 180 countries, the Hajj and Umrah pilgrimage can further compound the ongoing measles outbreaks. Vaccine hesitancy among Muslim populations should receive special attention in addition to general measles control efforts.
Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6
The rise in travel-associated measles infections—GeoSentinel, 2015–2019
Kristina M Angelo, Michael Libman, Philippe Gautret, Elizabeth Barnett, Martin P Grobusch …
Journal of Travel Medicine, Volume 26, Issue 6, 2019, taz046, https://doi.org/10.1093/jtm/taz046
The global threat of measles in recent years affects international travelers, and is acquired in both endemic and outbreak settings. The number of measles cases reported to GeoSentinel has risen each year since 2015 and demonstrates a high median age, short travel duration, and low measles
Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6
Yellow fever and Hajj 2019: from airline introduction of mosquitoes to expanding geography of transmission and vaccination challenges
Shahul H Ebrahim, MD, Ziad A Memish, MD
Journal of Travel Medicine, Volume 26, Issue 6, 2019, taz051, https://doi.org/10.1093/jtm/taz051
Yellow fever epidemiology is changing with large-scale epidemics in Africa, increased risk of urban outbreaks in Latin America, and spread to Asia. Therefore, in addition to the changing epidemiology, mosquito resurgence, and urbanization of yellow fever, the Hajj 2019 presents another challenge to the well-structured global strategy for YF Control.
Journal of Travel Medicine
Volume 26, Issue 6, 2019
https://academic.oup.com/jtm/issue/26/6
Measles and the 2019 Hajj: risk of international transmission
Sakshi Shetty, Maya Murmann, Ashleigh R Tuite, Alexander G Watts, Isaac Bogoch …
Journal of Travel Medicine, Volume 26, Issue 6, 2019, taz058, https://doi.org/10.1093/jtm/taz058
The current global increase in measles cases is associated with a small but non-negligible risk of an infected pilgrim arriving at the 2019 Hajj. Since even a single imported case can cause an outbreak in vulnerable populations, Saudi Arabia and countries with returning pilgrims should be alert for measles cases.
Lancet Respiratory Medicine
Sep 2019 Volume 7 Number 9 p721-826, e26-e28
http://www.thelancet.com/journals/lanres/issue/current
Series
Tuberculosis 2019
Insights and challenges in tuberculosis vaccine development
Helen McShane
Summary
Tuberculosis kills more people than any other pathogen and the need for a universally effective vaccine has never been greater. An effective vaccine will be a key tool in achieving the targets set by WHO in the End TB Strategy. Tuberculosis vaccine development is difficult and slow. Substantial progress has been made in research and development of tuberculosis vaccines in the past 20 years, and two clinical trial results from 2018 provide reason for optimism. However, many challenges to the successful licensure and deployment of an effective tuberculosis vaccine remain. The development of new tools for vaccine evaluation might facilitate these processes, and continued collaborative working and sustained funding will be essential.
Lancet Respiratory Medicine
Sep 2019 Volume 7 Number 9 p721-826, e26-e28
http://www.thelancet.com/journals/lanres/issue/current
Commission Update
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis
Keertan Dheda, Tawanda Gumbo,Gary Maartens, Kelly E Dooley, Megan Murray, Jennifer Furin,
Edward A Nardell, Robin M Warren, on behalf of The Lancet Respiratory Medicine drug-resistant tuberculosis Commission group
Summary
The Lancet Respiratory Medicine Commission on drug-resistant tuberculosis was published in 2017, which comprehensively reviewed and provided recommendations on various aspects of the disease. Several key new developments regarding drug-resistant tuberculosis are outlined in this Commission Update. The WHO guidelines on treating drug-resistant tuberculosis were updated in 2019 with a reclassification of second line anti-tuberculosis drugs. An injection-free MDR tuberculosis treatment regimen is now recommended. Over the past 3 years, advances in treatment include the recognition of the safety and mortality benefit of bedaquiline, the finding that the 9–11 month injectable-based ‘Bangladesh’ regimen was non-inferior to longer regimens, and promising interim results of a novel 6 month 3-drug regimen (bedaquiline, pretomanid, and linezolid). Studies of explanted lungs from patients with drug-resistant tuberculosis have shown substantial drug-specific gradients across pulmonary cavities, suggesting that alternative dosing and drug delivery strategies are needed to reduce functional monotherapy at the site of disease. Several controversies are discussed including the optimal route of drug administration, optimal number of drugs constituting a regimen, selection of individual drugs for a regimen, duration of the regimen, and minimal desirable standards of antibiotic stewardship. Newer rapid nucleic acid amplification test platforms, including point-of-care systems that facilitate active case-finding, are discussed. The rapid diagnosis of resistance to other drugs, (notably fluoroquinolones), and detection of resistance by targeted or whole genome sequencing will probably change the diagnostic landscape in the near future.
Nature Genetics
Volume 51 Issue 9, September 2019
https://www.nature.com/ng/volumes/51/issues/9
Editorial | 02 September 2019
Mendel for the modern era
The genome of the model genetic organism Pisum sativum, or pea plant, links nineteenth-century genetics to twenty-first-century genomics, serving as a symbol of how far the genetics field has developed and how greatly technologies have advanced. Almost every student’s introduction to genetics currently involves learning Mendel’s laws; we envision that genomics and genome sequencing will become just as foundational in the education of future geneticists.
Nature Genetics
Volume 51 Issue 9, September 2019
https://www.nature.com/ng/volumes/51/issues/9
Article | 02 September 2019 | Open Access
A reference genome for pea provides insight into legume genome evolution
The first annotated chromosome-level reference genome assembly for pea, Gregor Mendel’s original genetic model, provides insights into legume genome evolution and the molecular basis of agricultural traits for pea improvement.
Jonathan Kreplak, Mohammed-Amin Madoui[…] & Judith Burstin
New England Journal of Medicine
September 5, 2019 Vol. 381 No. 10
http://www.nejm.org/toc/nejm/medical-journal
Perspective
Toppling the Ethical Balance — Health Care Refusal and the Trump Administration
E. Sepper
A new rule from the U.S. Department of Health and Human Services creates a wide-ranging right to refuse to provide health care services. If it goes into effect, patient health and professional practice are likely to suffer.
Pediatrics
September 2019, VOLUME 144 / ISSUE 3
https://pediatrics.aappublications.org/content/144/3?current-issue=y
Articles
Early Childhood Vaccination Status of Preterm Infants
Annika M. Hofstetter, Elizabeth N. Jacobson, M. Patricia deHart, Janet A. Englund
Pediatrics Sep 2019, 144 (3) e20183520; DOI: 10.1542/peds.2018-3520
In this retrospective study, we used EHR and immunization information system data to compare early childhood vaccination of preterm and term/post term infants born between 2008 and 2013.
Pediatrics
September 2019, VOLUME 144 / ISSUE 3
https://pediatrics.aappublications.org/content/144/3?current-issue=y
Review Articles
Transmission of Vaccine-Strain Varicella-Zoster Virus: A Systematic Review
Mona Marin, Jessica Leung, Anne A. Gershon
Pediatrics Sep 2019, 144 (3) e20191305; DOI: 10.1542/peds.2019-1305
We reviewed the published experience with the use of live VZV vaccines to assess characteristics of secondary transmission of the vaccine-strain virus.
PharmacoEconomics
Volume 37, Issue 9, September 2019
https://link.springer.com/journal/40273/37/9
Systematic Review
Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions
Marina Treskova, Stefan M. Scholz, Alexander Kuhlmann
PLoS Medicine
http://www.plosmedicine.org/
(Accessed 7 Sep2019)
Collection Review
Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance
Christian Lienhardt, Andrew A. Vernon, Marco Cavaleri, Sumati Nambiar, Payam Nahid
| published 06 Sep 2019 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1002915
PLoS Medicine
http://www.plosmedicine.org/
(Accessed 7 Sep2019)
Research Article
Social network interventions for health behaviours and outcomes: A systematic review and meta-analysis
There has been a growing interest in understanding the effects of social networks on health-related behaviour, with a particular backdrop being the emerging prominence of complexity or systems science in public health. Social network interventions specifically use or alter the characteristics of social networks to generate, accelerate, or maintain health behaviours. We conducted a systematic review and meta-analysis to investigate health behaviour outcomes of social network interventions.
Ruth F. Hunter, Kayla de la Haye, Jennifer M. Murray, Jennifer Badham, Thomas W. Valente, Mike Clarke, Frank Kee
| published 03 Sep 2019 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1002890
PLoS One
http://www.plosone.org/
[Accessed 7 Sep2019]
Research Article
Vaccination timeliness and associated factors among preterm infants at a tertiary hospital in Uganda
Irene Nakatudde, Joseph Rujumba, Flavia Namiiro, Ali Sam, Jamir Mugalu, Philippa Musoke
Research Article | published 06 Sep 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0221902
PLoS One
http://www.plosone.org/
[Accessed 7 Sep2019]
Burden of influenza-associated respiratory hospitalizations in the Americas, 2010–2015
Rakhee S. Palekar, Melissa A. Rolfes, C. Sofia Arriola, Belsy O. Acosta, Patricia Alberto Guidos, Xiomara Badilla Vargas, Christina Bancej, Juliana Barbosa Ramirez, Elsa Baumeister, Alfredo Bruno, Maria Agüeda Cabello, Jufu Chen, Paula Couto, Francisco J. De Paula Junior, Rodrigo Fasce, Walquiria Ferreira de Almeida, Victor E. Fiesta Solorzano, Carlos Flores Ramírez, Natalia Goñi, Yadira Isaza de Moltó, Jenny Lara, Diana C. Malo, José L. Medina Osis, Homer Mejía, Lourdes Moreno Castillo, Desiree Mustaquim, Andrea Nwosu, Jenny Ojeda, Antonio Paredes Samoya, Paola A. Pulido, Hector M. Ramos Hernandez, Rudvelinda Rivera Lopez, Angel Rodriguez, Myriam Saboui, Hilda Salazar Bolanos, Adrián Santoro, Jose Eduardo Silvera, Paulina Sosa, Viviana Sotomayor, Lourdes Suarez, Marta Von Horoch, Eduardo Azziz-Baumgartner
Research Article | published 06 Sep 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0221479
PLoS One
http://www.plosone.org/
[Accessed 7 Sep2019]
Delayed second dose of oral cholera vaccine administered before high-risk period for cholera transmission: Cholera control strategy in Lusaka, 2016
Eva Ferreras, Belem Matapo, Elizabeth Chizema-Kawesha, Orbrie Chewe, Hannah Mzyece, Alexandre Blake, Loveness Moonde, Gideon Zulu, Marc Poncin, Nyambe Sinyange, Nancy Kasese-Chanda, Caroline Phiri, Kennedy Malama, Victor Mukonka, Sandra Cohuet, Florent Uzzeni, Iza Ciglenecki, M. Carolina Danovaro-Holliday, Francisco J. Luquero, Lorenzo Pezzoli
Research Article | published 30 Aug 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0219040
Abstract
Background
In April 2016, an emergency vaccination campaign using one dose of Oral Cholera Vaccine (OCV) was organized in response to a cholera outbreak that started in Lusaka in February 2016. In December 2016, a second round of vaccination was conducted, with the objective of increasing the duration of protection, before the high-risk period for cholera transmission. We assessed vaccination coverage for the first and second rounds of the OCV campaign.
Methods
Vaccination coverage was estimated after each round from a sample selected from targeted-areas for vaccination using a cross-sectional survey in to establish the vaccination status of the individuals recruited. The study population included all individuals older than 12 months residing in the areas targeted for vaccination. We interviewed 505 randomly selected individuals after the first round and 442 after the second round. Vaccination status was ascertained either by vaccination card or verbal reporting. Households were selected using spatial random sampling.
Results
The vaccination coverage with two doses was 58.1% (25/43; 95%CI: 42.1–72.9) in children 1–5 years old, 59.5% (69/116; 95%CI: 49.9–68.5) in children 5–15 years old and 19.9% (56/281; 95%CI: 15.4–25.1) in adults above 15 years old. The overall dropout rate was 10.9% (95%CI: 8.1–14.1). Overall, 69.9% (n = 309/442; 95%CI: 65.4–74.1) reported to have received at least one OCV dose.
Conclusions
The areas at highest risk of suffering cholera outbreaks were targeted for vaccination obtaining relatively high vaccine coverage after each round. However, the long delay between doses in areas subject to considerable population movement resulted in many individuals receiving only one OCV dose. Additional vaccination campaigns may be required to sustain protection over time in case of persistence of risk. Further evidence is needed to establish a maximum optimal interval time of a delayed second dose and variations in different settings.
Public Health Reports
Volume 134 Issue 5, September/October 2019
https://journals.sagepub.com/toc/phrg/134/5
Research
Completion of the Human Papillomavirus Vaccination Series Among Adolescent Users and Nonusers of School-Based Health Centers
Meaghan S. Munn, MPH, Meagan Kay, DVM, MPVM, Libby C. Page, MPH, Jeffrey S. Duchin, MD
First Published August 12, 2019; pp. 559–566
Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
http://www.paho.org/journal/index.php?option=com_content&view=featured&Itemid=101
6 Sep 2019
Initial care for migrants in Chile: status of a primary health care initiative after one year of implementation
Original research | Spanish |
Science
06 September 2019 Vol 365, Issue 6457
http://www.sciencemag.org/current.dtl
In Depth
Controversy over dengue vaccine risk
By Jon Cohen
Science06 Sep 2019 : 961-962 Restricted Access
All immunized Filipino kids should be tested, some say.
Summary
Shortly after Dengvaxia came to market in 2015, the Philippines launched a massive campaign to immunize children against the dreaded diseases. After about 1 million children were vaccinated, Sanofi Pasteur, the Paris-based maker of the product, revealed that ongoing clinical trials had found a rare, dangerous complication. Four distinct variants of dengue infect humans. In a well-known phenomenon, people infected with one strain who become infected with a second one become vulnerable to severe dengue, which can cause life-threatening shock and hemorrhagic fever. The vaccine, when given to children who had never been infected with dengue, primes some for that rare phenomenon of severe disease. Now, some researchers are calling for studies that would test the vaccinated children and identify the ones most at risk. They contend that if parents knew their children were at increased risk of severe disease, they could more aggressively seek care if they suspected dengue. This also might alleviate confusion for some parents who have blamed the vaccine for the death of their children. But no one has sponsored the study yet.
Tropical Medicine & International Health
Volume 24, Issue 9 Pages: i-iv, 1031-1137 September 2019
https://onlinelibrary.wiley.com/toc/13653156/current
Original Research Papers
Awareness and attitude towards human papillomavirus and its vaccine among females with and without daughter(s) who participated in cervical cancer screening in Shenzhen, China
Wei Lin, Yueyun Wang, Zhihua Liu, Bin Chen, Shixin Yuan, Bo Wu, Lin Gong
Pages: 1054-1063
First Published: 02 July 2019
Vaccine
Volume 37, Issue 39 Pages 5807-5908 (16 September 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/39
Review article Abstract only
Introducing rotavirus vaccine in the Universal Immunization Programme in India: From evidence to policy to implementation
Akash Malik, Pradeep Haldar, Arindam Ray, Anita Shet, … Rakesh Kumar
Pages 5817-5824
Vaccine
Volume 37, Issue 39 Pages 5807-5908 (16 September 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/39
Review article Abstract only
Timeliness and factors associated with rotavirus vaccine uptake among Australian Aboriginal and non-Aboriginal children: A record linkage cohort study
Parveen Fathima, Heather F. Gidding, Thomas L. Snelling, Peter B. McIntyre, … Hannah C. Moore
Pages 5835-5843
Abstract
Objectives
Rotavirus vaccines (RV), included in Australia’s National Immunisation Program from mid-July 2007, are unique in strict time limits for administration. Here, we report on timeliness of RV uptake, compare cumulative RV coverage to age 12 months with DTPa, and assess factors associated with receipt of RV among Aboriginal and non-Aboriginal children.
Methods
Birth records for 681,456 children born in two Australian states in 2007–2012 were probabilistically linked to national immunisation records. We assessed on-time coverage (defined as receipt of vaccine dose between 4 days prior to scheduled date and the recommended upper limit) for RV and compared this to diphtheria-tetanus-pertussis (DTPa) vaccine. Logistic regression modelling was used to assess independent determinants of receipt of RV.
Results
Compared to non-Aboriginal infants, on-time RV coverage was lower for all doses among Aboriginal infants. Post the upper age limit of RV dose2, DTPa dose2 coverage increased by 9–16% to ≥90%, whereas RV coverage remained around 77% (Aboriginal) and 85% (non-Aboriginal). Compared to first-born children, the adjusted odds of receiving ≥1 RV dose if born to a mother with ≥3 previous births was 0.30 (95%CI: 0.27–0.34) among Aboriginal, and 0.53 (95%CI: 0.51–0.55) among non-Aboriginal children. Prematurity (<33 weeks), low birthweight (<1500 g), maternal age <20 years, maternal smoking during pregnancy and living in a disadvantaged area were independently associated with decreased vaccine uptake.
Conclusions
Aboriginal children are at greater risk of rotavirus disease than non-Aboriginal children and delayed vaccine receipt is substantially higher. Although specific programs targeting groups at risk of delayed vaccination might improve RV coverage, relaxation of upper age restrictions is most readily implementable, and its overall risk-benefit should be evaluated.
Vaccine
Volume 37, Issue 39 Pages 5807-5908 (16 September 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/39
Review article Abstract only
Timeliness of immunisations in preterm infants in the Netherlands
Elsbeth D.M. Rouers, Guy A.M. Berbers, Josephine A.P. van Dongen, Elisabeth A.M. Sanders, … Patricia Bruijning-Verhagen
Pages 5862-5867
Vaccine
Volume 37, Issue 39 Pages 5807-5908 (16 September 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/39
Research article Open access
Feasibility of case-control and test-negative designs to evaluate dengue vaccine effectiveness in Malaysia
Joshua Nealon, Wei-Yin Lim, Annick Moureau, Sharon Linus Lojikip, … Amar-Singh HSS
Pages 5891-5898
Vaccine
Volume 37, Issue 39 Pages 5807-5908 (16 September 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/39
Research article Open access
Feasibility of case-control and test-negative designs to evaluate dengue vaccine effectiveness in Malaysia
Joshua Nealon, Wei-Yin Lim, Annick Moureau, Sharon Linus Lojikip, … Amar-Singh HSS
Pages 5891-5898
From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary
Nature Immunology
Published: 02 September 2019
Comment
Vaccine hesitancy and coercion: all eyes on France
JK Ward, P Peretti-Watel, A Bocquier, V Seror, P Verger –
With record levels of vaccine hesitancy and one of the most drastic reinforcements of vaccine mandates in recent years, there is much to learn from the French experience.
vaccines and global health :: ethics and policy 